arrow
O

Ondřej Fiala

d aron research foundation ets
H指数:23
被引数:1,901

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis

基于性别的中危/高危乳头状、嗜酸性细胞和未分类肾细胞癌一线免疫联合疗法分析:ARON-1研究的亚组分析

2026-08-300
OA
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)

基线疾病特征和铂类药物敏感性作为顺铂为基础化疗、阿维鲁姆单抗维持治疗和恩沃利单抗维多汀序贯疗法在晚期尿路上皮癌中的预后预测因素(ARON-2EV研究)

2026-07-290
PRE
Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)
2026-07-290
OA
Early systemic inflammatory–metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab

早期系统性炎症-代谢轨迹表型与接受纳武利尤单抗治疗的转移性肾细胞癌患者的生存结局相关

2026-07-050
OAAI
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)

HERO评分在恩沃利单抗治疗的转移性尿路上皮癌中的真实世界预后评估(ARON-2EV研究)

2026-07-010
OAAI
Prognostic Role of Serum Neuron-Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

基线血清神经元特异性烯醇化酶的预后作用及其在经雄激素受体信号抑制剂治疗的转移性去势抵抗性前列腺癌中的早期动态变化

2026-05-260
OAAI
Monogenic forms of Parkinson's disease: a Czech cohort study

帕金森病的单基因形式:一项捷克队列研究

2026-05-010
PRE
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors

局部治疗在初诊低体积转移性激素敏感前列腺癌患者中的应用——该类患者接受雄激素受体通路抑制剂治疗

2026-03-300
OAAI
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

恩扎卢替尼在转移性激素敏感前列腺癌中的应用:国际、多中心真实世界ARON-3研究的结果

2026-01-080
OAAI
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

转移时间作为转移性尿路上皮癌的预后因素:ARON-2研究的结果

2025-11-210
PRE
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

肾细胞癌辅助性帕博利珠单抗的实证据:多中心真实世界ARON-1研究的结果

2025-11-140
OAAI
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort

在铂类化疗和帕博利珠单抗治疗后的转移性尿路上皮癌中恩沃利单抗维得尼单抗的疗效:ARON-2EV队列的多中心真实世界分析

2025-11-030
OAAI
IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations

IUC24394-87 接受一线免疫联合治疗的转移性肾细胞癌患者Meet-URO评分更新

2025-08-290
OAAI
Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab

质子泵抑制剂或心血管药物联合使用对接受纳武利尤单抗治疗转移性肾细胞癌患者生存结局的影响

2025-08-020
OAAI
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

基于免疫的组合疗法在非透明细胞肾细胞癌中/高风险患者中的应用:ARON-1研究的结果

2025-07-290
PRE